Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Sujan Piya, PhD, Seemana Bhattacharya, PhD, Hong Mu, MD PhD, Vivian Ruvolo, MS, Natalia Baran, PhDMD, Teresa McQueen, MS, R. Eric Davis, MD, Yimin Qian, PhD, Kanak Raina, PhD, M. James You, MD PhD, Marina Y. Konopleva, MD PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2018) 132 (Supplement 1): 890.

https://doi.org/10.1182/blood-2018-99-115692

Published: 2018

Journal Articles

BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825 Targets Both NOTCH1-MYC Regulatory Circuit and Leukemia-Microenvironment in T-ALL

Sujan Piya, PhD, Hong Mu, MD PhD, Seemana Bhattacharya, PhD, Teresa McQueen, MS, Richard E Davis, BSPharm, MS, Vivian Ruvolo, PhD, Natalia Baran, PhD MD, Yimin Qian, PhD, Kanak Raina, PhD, Craig M Crews, PhD, M. James You, MD PhD, Patrick Zweider McKay, MDPhD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2017) 130 (Supplement 1): 716.

https://doi.org/10.1182/blood.V130.Suppl_1.716.716

Published: 2017

Journal Articles

Targeted Therapy for AML Expressing RUNX1 Mutation

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Courtney D. DiNardo, MDMSc, Yimin Qian, PhD, Kanak Raina, PhD, Koichi Takahashi, MD, Tapan Kadia, MD, Dyana T. Saenz, PhD, Agnieszka J Nowak, Baohua Sun, MD PhD, Craig M Crews, PhD, Kapil N. Bhalla, MD

Blood (2017) 130 (Supplement 1): 2472.

https://doi.org/10.1182/blood.V130.Suppl_1.2472.2472

Published: 2017

Journal Articles

Targeted Therapy with BET Protein and β Catenin Antagonists Against Ruxolitinib Resistant Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Dyana T. Saenz, PhD, Warren Fiskus, BSc,PhD, Taghi Manshouri, Yimin Qian, PhD, Kanak Raina, PhD, David N Saenz, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, Baohua Sun, MD PhD, Srdan Verstovsek, MD PhD, Craig M Crews, PhD, Kapil N. Bhalla, MD

Blood (2017) 130 (Supplement 1): 1239.

https://doi.org/10.1182/blood.V130.Suppl_1.1239.1239

Published: 2017

Journal Articles

Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells

Baohua Sun, MD PhD, Warren Fiskus, BSc,PhD, Kanak Raina, PhD, Yimin Qian, PhD, Andrew Crew, Dyana T. Saenz, PhD, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, David N Saenz, Craig M Crews, PhD, Kapil N. Bhalla, MD

Blood (2017) 130 (Supplement 1): 1265.

https://doi.org/10.1182/blood.V130.Suppl_1.1265.1265

Published: 2017

Journal Articles

Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells

Baohua Sun, MD PhD, Warren Fiskus, PhD, Liang Zhang, MD PhD, Kanak Raina, PhD, Kevin Coleman, PhD, Jim Winkler, PhD, Yimin Qian, PhD, Andrew Crew, PhD, Angela Shen, MD, Dyana T Saenz, PhD, Christopher P Mill, PhD, Michael Wang, MD, Craig Crews, PhD, Kapil N. Bhalla, MD

Blood (2016) 128 (22): 1058.

https://doi.org/10.1182/blood.V128.22.1058.1058

Published: 2016

Journal Articles

Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Dyana T Saenz, PhD, Warren Fiskus, PhD, Kanak Raina, PhD, Taghi Manshouri, PhD, Kevin Coleman, PhD, Jim Winkler, PhD, Yimin Qian, PhD, Andrew Crew, PhD, Angela Shen, MD, Christopher P Mill, PhD, Baohua Sun, MD PhD, Srdan Verstovsek, MD PhD, Craig Crews, PhD, Kapil N. Bhalla, MD

Blood (2016) 128 (22): 747.

https://doi.org/10.1182/blood.V128.22.747.747

Published: 2016

Journal Articles

BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects

Sujan Piya, PhD, Seemana Bhattacharya, PhD, Hong Mu, MD PhD, Philip L Lorenzi, PhD, Teresa McQueen, MS, Eric Richard Davis, MD, Vivian Ruvolo, MS, Natalia Baran, PhD, Yimin Qian, PhD, Craig Crews, PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2016) 128 (22): 748.

https://doi.org/10.1182/blood.V128.22.748.748

Published: 2016

Journal Articles

BRD4 Degradation By Protacs Represents a More Effective Therapeutic Strategy Than BRD4 Inhibitors in DLBCL

Jing Lu, PhD, Yimin Qian, PhD, Kanak Raina, PhD, Martha Altieri, MS, Hanqing Dong, PhD, Jing Wang, PhD, Xin Chen, PhD, Andrew Crew, PhD, Kevin Coleman, PhD, Craig Crews, PhD, James Winkler, PhD

Blood (2015) 126 (23): 2050.

https://doi.org/10.1182/blood.V126.23.2050.2050

Published: 2015

Journal Articles

BRD4 Proteolysis Targeting Chimera (PROTAC) Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Leukemias and Overcomes Stroma Mediated Resistance By Modulating Surface Expression of CXCR4

Sujan Piya, Teresa McQueen, Duncan Mak, BSc, MPhil, Marina Konopleva, MD PhD, Patrick Zweidler-McKay, MD PhD, Jing Lu, PhD, Yimin Qian, PhD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2015) 126 (23): 675.

https://doi.org/10.1182/blood.V126.23.675.675

Published: 2015

Journal Articles

Proteolytic Targeting Chimeric Molecules (PROTACs) Specific for Bromodomain-Containing Protein (BRD) 4 Are Active Against Pre-Clinical Models of Multiple Myeloma

Xiaohui Zhang, MD, PhD, Jing Lu, PhD, Yimin Qian, PhD, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 917.

https://doi.org/10.1182/blood.V126.23.917.917

Published: 2015

NARROW

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825 Targets Both NOTCH1-MYC Regulatory Circuit and Leukemia-Microenvironment in T-ALL

Targeted Therapy for AML Expressing RUNX1 Mutation

Targeted Therapy with BET Protein and β Catenin Antagonists Against Ruxolitinib Resistant Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells

Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells

Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects

BRD4 Degradation By Protacs Represents a More Effective Therapeutic Strategy Than BRD4 Inhibitors in DLBCL

BRD4 Proteolysis Targeting Chimera (PROTAC) Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Leukemias and Overcomes Stroma Mediated Resistance By Modulating Surface Expression of CXCR4

Proteolytic Targeting Chimeric Molecules (PROTACs) Specific for Bromodomain-Containing Protein (BRD) 4 Are Active Against Pre-Clinical Models of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only